进入创新通道！硼中子俘获治疗系统

Core Viewpoint - The article discusses the approval and significance of the Boron Neutron Capture Therapy (BNCT) system developed by Guoke Neutron Medical Technology Co., Ltd., highlighting its potential as a new cancer treatment method with advanced precision and lower side effects [1][3][20]. R&D Background - BNCT is recognized as the "fifth cancer treatment method" after surgery, traditional radiotherapy, chemotherapy, and immunotherapy, particularly effective for hard-to-treat cancers like glioblastoma, head and neck cancer, and melanoma [2]. - The global BNCT market is estimated to be several hundred million dollars in 2023, with a projected CAGR of 10%-15% by 2030, primarily in Japan, the USA, and Europe [2]. - Japan's Sumitomo Heavy Industries and Stella Pharma launched the first BNCT device and boron drug in 2020, with treatment costs around tens of thousands of dollars per session [2]. About the BNCT System - The BNCT system developed by Guoke Neutron Medical Technology utilizes neutron and boron reactions to precisely kill tumor cells, marking the success of China's first self-owned intellectual property BNCT device [3][20]. - The device consists of a Radio Frequency Quadrupole (RFQ) accelerator, neutron generation system, and treatment room, designed to treat cancers that are difficult to manage with conventional methods [5]. Technical Analysis of BNCT - BNCT employs a two-pronged approach combining radiation and drug therapy, specifically targeting infiltrative and metastatic cancers [6]. - The treatment involves injecting boron-containing drugs that accumulate in tumor cells, followed by neutron irradiation, which leads to a nuclear reaction that effectively destroys cancer cells while sparing healthy tissue [9][13]. Advantages of BNCT - BNCT requires only 1-2 treatment sessions compared to over 30 sessions for conventional therapies, significantly reducing treatment duration [10][13]. - The treatment's precision is enhanced by the biological targeting of boron drugs, minimizing damage to surrounding healthy tissues [13]. Product Development History - The development of BNCT in China began in 2006 under the "973" program, with significant milestones achieved over the years, including the establishment of the first domestic RFQ accelerator and the successful installation of the first clinical BNCT device in Dongguan [14][15]. Company Overview - Guoke Neutron Medical Technology Co., Ltd. was established in 2021, focusing on the R&D, production, and marketing of high-end medical equipment for BNCT [20]. - The company has successfully completed clinical device design and testing, with high operational efficiency reported for its installed BNCT equipment [17][19].